Loading clinical trials...
Loading clinical trials...
Phase I Study of Mogamulizumab (M) in Combination With Brentuximab Vedotin (BV) in Previously Treated Cutaneous T Cell Lymphoma (CTCL) and Mycosis Fungoides (MF)
Conditions
Interventions
Mogamulizumab
Brentuximab vedotin
Locations
1
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Start Date
May 1, 2023
Primary Completion Date
April 30, 2026
Completion Date
July 31, 2026
Last Updated
April 9, 2026
NCT05589896
NCT06207812
NCT07356245
NCT06588868
NCT06716658
NCT06470451
Lead Sponsor
University of Alabama at Birmingham
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions